Pfizer takes out Hospira for $90 a share. No biggie, what's another $15 1/2 billion of cash amongst friends? I guess a few billion here and a few billion there means nothing any more? A 39% premium? Pretty soon, we will have 1 remaining ginormous Pharma company who owns the entire space. I remember back in [...]
Vertex pulled Incivek, Merck pulls Victrelis, and what will J&J do with the other HEP C compound competing against Gilead and Abbvie? Merck has a few rabbits up their sleeve with a potential approval this year and some M&A, but for now, the battle continues. SMZ
by Anette Breindl, PhD Twenty-four years after the National Institutes of Health (NIH) established the Office of Research on Women’s Health, and 21 years after the NIH Revitalization Act of 1993 first required that women be included in clinical trials, certainly the letter of the law has been achieved. Women are now the majority of participants [...]
GSK - NYSE - Nasty Chart, looks like a test of the 2012 low is coming. GlaxoSmithKline ($GSK) is making big cost cuts to boost its finances next year as sales of its $8.25 billion asthma med Advair are deflated by competition, generic and otherwise. With the U.S. being the biggest market for the [...]
We have bad news and good news about patent expirations next year. The bad? When you tot up the billions of sales at risk of patent expiration in 2015, the result is $44 billion, the biggest number since the debacle of 2012. That year, $53 billion worth of drugs fell off patent--and many drugmakers are [...]
Tony Coles, the chief executive who sold Onyx Pharmaceuticals to Amgen AMGN -2.45% for $10.4 billion in 2013, is starting a new company that will use yeast to try and discover new treatments for Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease.) The new startup, Yumanity, will be based in [...]
Drugmakers that complain about the growing cost to bring new molecular entities to market aren’t exaggerating, according to a study released last month by the Tufts Center for the Study of Drug Development (CSDD). Even with the initiation of mechanisms to speed drug development such as breakthrough therapy designation and accelerated review, developing a medicine [...]
Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of the year; we will round out the entire year's activity in another report early next year. The top 10 deals [...]
ig pharma Merck (NYSE:MRK) agreed to buy antibiotic specialist Cubist Pharmaceuticals (NASDAQ:CBST) Monday in a deal valued at $9.5 billion. Cubist soared 35% in the stock market today, while Merck dropped a fraction. Merck is acquiring Cubist for $102 a share in cash, yielding an equity value of $8.4 billion, plus $1.1 billion in net [...]
The biotech index is more than a triple bagger ramp since 2010. Know that as long as the biopharm has equity (capital), research will continue with reckless abandon. Hopefully, with this ramp, the old guard will implement technology to bring more accurate outcomes. szimm
